- Conditions
- Colorectal Cancer, Familial Adenomatous Polyposis
- Interventions
- Celecoxib, Placebo, eflornithine, Laboratory biomarker analysis, Questionnaire administration
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2009
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–37
of 37
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Neuroblastoma
- Interventions
- Difluoromethylornithine (DFMO)
- Drug
- Lead sponsor
- Giselle Sholler
- Other
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 441 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2033
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Oakland, California + 38 more
- Conditions
- Neuroblastoma
- Interventions
- DFMO, Etoposide
- Drug
- Lead sponsor
- Giselle Sholler
- Other
- Eligibility
- Not listed
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 7
- States / cities
- Orange, California • Hartford, Connecticut • Orlando, Florida + 4 more
- Conditions
- Pseudofolliculitis Barbae
- Interventions
- 15% Eflornithine Hdyrochloride
- Drug
- Lead sponsor
- Hordinsky, Maria K., MD
- Individual
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1999 – 2000
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Osteosarcoma, Ewing Sarcoma
- Interventions
- Eflornithine, Topotecan, Cyclophosphamide, Vincristine, Doxorubicin, Ifosfamide, Etoposide, Cisplatin, Methotrexate
- Drug
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 0 Years to 50 Years
- Enrollment
- 406 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2036
- U.S. locations
- 3
- States / cities
- Tampa, Florida • Portland, Oregon • Hershey, Pennsylvania
- Conditions
- Diffuse Glioma, Malignant Glioma
- Interventions
- Biospecimen Collection, Computed Tomography, Eflornithine, Magnetic Resonance Imaging, Polyamine Transport Inhibitor AMXT-1501 Dicaprate, Resection, Microdialysis, Placement
- Procedure · Drug · Device
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Other Benign Neoplasm of Skin, Unspecified
- Interventions
- Diclofenac Na gel, Eflornithine HCL ointment
- Drug
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 184 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 3
- States / cities
- Tucson, Arizona
- Conditions
- Non-melanoma Skin Cancer
- Interventions
- Solaraze and Vaniqa
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 2
- States / cities
- Birmingham, Alabama
- Conditions
- Precancerous Condition
- Interventions
- placebo, eflornithine, sulindac, laboratory biomarker analysis
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 375 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2008
- U.S. locations
- 1
- States / cities
- Orange, California
- Conditions
- Prostate Cancer
- Interventions
- eflornithine, Placebo
- Drug
- Lead sponsor
- Thomas E. Ahlering
- Other
- Eligibility
- 35 Years to 70 Years · Male only
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2012
- U.S. locations
- 1
- States / cities
- Orange, California
- Conditions
- Prostate Cancer
- Interventions
- bicalutamide, eflornithine, oral eflornithine placebo, oral bicalutamide placebo
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2003
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Glioblastoma, IDH-wildtype, Glioblastoma, Glioblastoma Multiforme, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, GBM, Astrocytoma, Astrocytoma, IDH-Mutant
- Interventions
- Eflornithine (Dose Level -1), Eflornithine (Dose Level 2), Temozolomide
- Drug
- Lead sponsor
- Orbus Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Detroit, Michigan • New York, New York + 5 more
- Conditions
- High Risk Neuroblastoma, Recurrent Neuroblastoma, Refractory Neuroblastoma
- Interventions
- Dinutuximab, Eflornithine Hydrochloride, Irinotecan Hydrochloride, Sargramostim, Temozolomide
- Biological · Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year and older
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 124
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 100 more